Clinical Trial Update: A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (SHR-A1811) for PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer | Phase 3 | Status: RECRUITING